AstraZeneca Plc’s diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration. The FDA’s report, posted on the agency’s website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the drug’s safety. Onglyza was approved in 2009. A company-sponsored trial of more than 16,000 patients known as SAVOR previously showed patients taking Onglyza, also known as saxagliptin, had an increased risk of hospitalization due to heart failure.